NCT06021626 - A Study of CRD3874-SI in People With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions

SarcomaMerkel Cell Carcinoma

Interventions

DRUG

CRD3874

"Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI.~Cohort CRD3874-SI Dose level (mg/kg)~1. 0.1~2. 0.3~3. 0.9~4. 1.8~5. 2.7~6. 4.05"

Trial Locations (7)

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale